This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Protocol for interpretation of anti-HBs result after pre-exposure vaccination

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The schedule for the particular vaccine should always be checked before proceeding

  • vaccine is given intramuscularly into the deltoid region. The buttock should not be used as this reduces the efficacy of the vaccine, but the anterolateral thigh may be used
  • the immune status is checked 1-2 months after the third dose of vaccine. The antibody (anti-HBS) levels defines further intervention
  • an example of an immunisation schedule following the result of the antibody level after the primary vaccination course is presented

There are many different immunisation schedules for hepatitis B vaccine which depend on the vaccine product used and how quickly protection is needed for pre or post exposure.

Testing for response to vaccination

Hepatitis B vaccines are highly effective; around 90% of adults respond to vaccines adequately.

Poor responses are mostly associated with age over 40 years, obesity and smoking

  • lower seroconversion rates have also been reported in people who have alcohol dependency, particularly those with advanced liver disease
  • patients who are immunosuppressed or on renal dialysis may respond less well than healthy individuals and may require larger or more frequent doses of vaccine
  • vaccine is not effective in patients with acute hepatitis B, and is not necessary for individuals known to have markers of current (HBsAg) or past (anti-HBc) infection. However, immunisation should not be delayed while awaiting any test results for current or past infection
  • testing for evidence of immunity post immunisation (anti-HBs) is not routinely recommended although is required for particular risk groups e.g. those with occupational exposure.

Those at risk of occupational exposure

  • in those at risk of occupational exposure, particularly healthcare and laboratory workers, anti-HBs titres should be checked one to two months after the completion of a primary course of vaccine
    • under the Control of Substances Hazardous to Health (COSHH) Regulations, individual workers have the right to know whether or not they have been protected
      • such information allows appropriate decisions to be made concerning postexposure prophylaxis following known or suspected exposure to the virus

  • antibody responses to hepatitis B vaccine vary widely between individuals
    • preferable to achieve anti-HBs levels above 100mIU/ml, although levels of 10mIU/ml or more are generally accepted as enough to protect against infection
    • some anti-HBs assays are not particularly specific at the lower levels, and anti-HBs levels of 100mIU/ml provide greater confidence that a specific response has been established

Assessment of response to hepatitis B vaccine:

  • responders with anti-HBs levels greater than or equal to 100mIU/ml do not require any further primary doses
    • in immunocompetent individuals, once a response has been established further assessment of antibody levels is not indicated

  • responders with anti- HBs levels of 10 to 100mIU/ml
    • should receive one additional dose of vaccine at that time
    • in immunocompetent individuals, further assessment of antibody levels is not indicated
    • current advice is that healthcare and laboratory workers should be offered a single booster dose of vaccine, once only, five years after the primary immunisation

  • anti-HBs level below 10mIU/ml
    • classified as a non-response to vaccine, and testing for markers of current or past infection is good clinical practice
    • in non-responders, a repeat course of vaccine is recommended, followed by retesting one to two months after the second course
    • those who still have anti-HBs levels below 10mIU/ml, and who have no markers of current or past infection, will require HBIG for protection if exposed to the virus (1)

Notes:

  • in chronic renal failure
    • protection may persist only as long as anti-HBs levels remain above 10mIU/ml. Antibody levels should, therefore, be monitored annually and if they fall below 10mIU/ml, a booster dose of vaccine should be given to patients who have previously responded to the vaccine (1)

  • other guidance has been detailed about how to manage an anti-HBS response of below 10 iu per litre (2)
    • if the anti-HBS level is below 10 iu per litre then check core antibody (anti-HBC)
      • if the anti-HBC is positive then this indicates HBV infection in the past
      • if the anti-HBC is negative then repeat or complete second accelerated full course. A response may be achieved via the use of a higher-dose vaccine
      • if no response and anti-HBC negative then the patient should be advised that he is not immune and will require hepatitis B specific immunoglobulin after high-risk exposure
    • if there is any response (>= 10 iu per litre) then the patient requires a booster 5 years later

Reference:

  • The Green Book. Chapter 18 - Hepatitis B (April 2019)
  • Prescriber (2000), 11, (7), 45-54.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.